Understanding how epigenetic factors influence prostate cancer
Official title: Towards characterization of Epigenetic targets in Prostate Cancer
Funded at University of Pennsylvania · NIH-11105090 · Data updated 2026-11-12
This study is looking at how advanced prostate cancer becomes resistant to certain treatments, and it aims to find new ways to help improve care for patients dealing with this tough condition by exploring how specific proteins interact with the cancer cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $371,719 |
| NIH project number | 1R01CA299870-01 |
| Project ID | NIH-11105090 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer, especially those experiencing resistance to androgen-targeted therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not undergone androgen-targeted treatments may not benefit from this research.
What this research studies
This research focuses on advanced prostate cancer, particularly how cancer cells become resistant to treatments that target the androgen receptor (AR). It aims to identify and characterize specific proteins and cofactors that interact with AR, which may contribute to the progression of the disease. By understanding these mechanisms, the research seeks to develop new therapeutic strategies that could improve treatment outcomes for patients with metastatic castration-resistant prostate cancer. The study will involve laboratory experiments and analysis of cancer cell behavior in response to various treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for men with advanced prostate cancer, particularly those who have developed resistance to current therapies.
How similar studies have gone: Previous research has shown promising results in targeting epigenetic factors in cancer treatment, indicating that this approach could be beneficial.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Asangani, Irfan Ahmed — University of Pennsylvania
- Study coordinator: Asangani, Irfan Ahmed
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.